


Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
53437-A-PCT-
US/JPW/SHSSerial No.
09/534,711

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Applicants
Livingston, et al.Filing Date
March 24, 2000Group
1642

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation
					Yes No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Cheung, N-K. V., et al. (1987) "Ganglioside GD2 specific monoclonal antibody 3F8: a phase-I study in patients with neuroblastoma and malignant melanoma." <u>J. Clin. Oncol.</u> 5: 1430-1440 (Exhibit 5)
	Dippold, W. G., et al. (1985) "Immunohistochemical localization of ganglioside GD3 in human malignant melanoma, epithelial tumors, and normal tissues." <u>Cancer Res.</u> 45: 3699-3705 (Exhibit 6)
	Finn, O. J., (1995) "Immunotherapy: tumor vaccines." <u>Proc. Am. Assoc. Cancer Res.</u> 36: 675 (Exhibit 7)
	Hamilton, W. B., et al. (1993) "Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography." <u>Int. J. Cancer</u> 53: 566-573 (Exhibit 8)

EXAMINER

DATE CONSIDERED

4/11/02


*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
53437-A-PCT-
US/JPW/SHS

Serial No.

09

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicants
Livingston, et al.Filing Date
March 24, 2000Group
1642RECEIVED
FEB 14 2002
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Helling, F., et al. (1994) "GD3 vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines." <u>Cancer Res.</u> 54: 197-203 (Exhibit 9)
	Helling, F. et al. (1995) "GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21." <u>Cancer Res.</u> 55: 2783-2788 (Exhibit 10)
	Kensil, C. R., et al. (1991) "Separation and characterization of saponins with adjuvant activity from <i>Quillaja saponaria</i> molina cortex." <u>J. Immunology</u> 146: 431-437 (Exhibit 11)
	Livingston, P. O., et al. (1994) "Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside." <u>J. Clin. Oncol.</u> 12: 1036-1044 (Exhibit 12)


EXAMINER

DATE CONSIDERED

4/11/02

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
53437-A-PCT-
US/JPW/SHSSerial No.
09/534,711INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicants
Livingston, et al.Filing Date
March 24, 2000Group
1642

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


	Livingston, P.O., et al. (1994) "Phase I trial of immunological adjuvant QS-21 with a GM2 ganglioside-KLH conjugate vaccine in patients with malignant melanoma." <u>Vaccine</u> 12: 1275-1280 (Exhibit 13)
	Livingston, P.O. (1995) "Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines." <u>Immunological Reviews</u> 145: 147-166 (Exhibit 14)
	Livingston, P.O., et al. (1989) "Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside." <u>Cancer Res.</u> 49: 7045-7050 (Exhibit 15)
	Livingston, P.O., et al. (1997) "Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2-KLH is increased by IgG antibodies." <u>Ca. Immunol. And Immunotherapy</u> 43: 324-330 (Exhibit 16)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
53437-A-PCT-
US/JPW/SHSSerial No.
09/534,712INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicants
Livingston, et al.Filing Date
March 24, 2000Group
1642

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Nilsson, O., et al. (1986) "Detection of a ganglioside antigen associated with small cell lung carcinomas using monoclonal antibodies directed against fucosyl-GM1." <u>Cancer Res.</u> 46: 1403-1407 (Exhibit 17)
	Ragupathi, G. (1997) "Phase I trial with GD3-lactone-KLH conjugate and immunological adjuvant QS-21 vaccine with malignant melanoma." <u>Proc. Am. Assoc. Cancer Res.</u> 38: 398 (Exhibit 18)
	Vangsted, A.J., et al. (1991) "Immunochemical detection of a small cell lung cancer-associated ganglioside (FucGM1) antigen in serum." <u>Cancer Research</u> 51: 2879-2884 (Exhibit 19)
	Zhang, S., et al. (1997) "Selection of tumor antigens as targets for immune attack using immunohistochemistry. I. Focus on gangliosides." <u>Int. J. Cancer</u> 73: 42-49 (Exhibit 20)

EXAMINER

DATE CONSIDERED

4/11/02

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.